Accelerating Complex Respiratory Clinical Trials with Specialized Expertise
According to the Global Burden of Disease Study 2019, over 450 million patients suffer from chronic respiratory diseases globally with asthma having the highest prevalence. Moreover, around 4 million deaths were caused by respiratory conditions such as COPD and lung cancers. The total deaths and prevalence of chronic respiratory disease have increased considerably in the last 3 decades. This highlights the urgent need for safe and effective therapeutic measures. Despite this enormous unmet need, fewer new drugs have been developed in respiratory due to the complex nature of trials, higher cost, and longer duration. At Medpace, we make this complex seamless. We are a full-service Clinical Research Organization (CRO) with the experience to navigate and overcome such challenges.
Accelerate your path to approval with guidance from our team of medical, operational, and regulatory experts. Our extensive experience and consistent track record of success ensures the flexibility to adapt to the unique needs of each respiratory trial, overcome complex challenges and maximize your trial budget.
Making the Complex Seamless® in Global Respiratory Trials
Drive the successful execution of respiratory/pulmonary clinical trials through a partner with strong communication, coupled with early planning and experience collaborating with global regulatory authorities. For over 30 years, Sponsors across emerging biotechnology and global pharmaceutical companies have trusted Medpace to lead their clinical development.
Gain a competitive advantage through our global expertise and experience while benefiting from:
Comprehensive support via our dedicated global regulatory submissions and global regulatory affairs teams
Strategic guidance from our dedicated, in-house patient recruitment and retention teams who are experienced in recruiting patient populations to accelerate patient enrollment
A patient centric approach to minimize patient burden while helping yield successful outcomes in terms of study design, participation, adherence, satisfaction, and data collection
Strong, long-term relationships with investigators, experienced sites, networks, and key opinion leaders (KOLs) help facilitate strategic site selection, start-up, and recruitment efforts
ClinTrak®, Medpace’s proprietary Study Management system, provides aggregate data and reporting to support all aspects of a project to enhance and streamline study management
Medpace has the global experience to support Phase I-IV clinical trials across a wide range of indications, including but not limited to:
Asthma
Acute Respiratory Distress Syndrome (ARDS)
Alpha-1 Antitrypsin Deficiency (AATD)
Bronchiectasis
Chronic Obstructive Pulmonary Disease (COPD)
Cystic fibrosis
Emphysema
Idiopathic Pulmonary Fibrosis (IPF)
Interstitial Lung Disease
Lung Cancer
Mesothelioma
Obstructive Sleep Apnea
Bacterial and Viral Pneumonia
Pulmonary Embolism
Pulmonary Hypertension
Sarcoidosis
Respiratory Clinical Trial Experts
In-house, pulmonologists, clinical immunologists, and allergists add an additional layer of medical and scientific expertise and are embedded within the project team throughout the lifecycle of your trial. They provide leadership, consulting with Sponsors, along with training project teams and investigative sites to ensure our operational strategy is firmly aligned with your scientific and medical objectives. Additionally, our operational teams, including clinical trial managers and program coordinators, are therapeutically aligned to provide specialized training to sites and help mitigate challenges.
Alpha-1 Antitrypsin Deficiency (AATD) Consortium of Experts
The Medpace AATD Consortium brings together leading medical, operational, and regulatory experts from around the world who are dedicated to advancing AATD clinical development. The cross-functional team meets regularly to share lessons learned, apply best practices, and develop innovative solutions tailored to the unique challenges of AATD. With a shared commitment to accelerating progress, the consortium focuses on seamless execution of global AATD trials through collaboration and innovation.
Key focus areas include:
Analyzing the evolving competitive landscape to optimize country selection and enrollment
Developing and refining global patient recruitment strategies
Creating project management tools to accelerate startup and reduce operational hurdles
Sharing site-specific insights from KOLs to minimize duplication of efforts
Supporting ongoing education and training of new members
“Together we can make the world breathe easy. Delighted to work among scientifically driven individuals who work together towards the development of novel therapeutics and routes of drug delivery.”
